You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK)附屬與Inventiva簽訂正式許可協議
格隆匯 09-22 16:35

格隆匯9月22日丨中國生物製藥(01177.HK)發佈公吿,2022年9月22日,公司附屬公司正大天晴與Inventiva S. A.簽訂正式許可協議以在中國大陸、中國香港、中國澳門、中國台灣(“大中華區”)開發、生產並商業化拉尼蘭諾 (lanifibranor)。該產品是Inventiva的核心產品,用於治療非酒精性脂肪性肝炎(“NASH”)和其他潛在的代謝疾病。

Inventiva是一家處在臨牀階段的生物製藥公司,專注於在NASH、黏多糖貯積症及其他存在未滿足臨牀需求領域的口服小分子藥物研發工作。正大天晴將向Inventiva支付1200萬美元的首付款及最高不超過4000萬美元的潛在臨牀及註冊里程碑付款,以獲得該產品在大中華區的獨家許可。該產品在大中華區獲批上市後,正大天晴將支付額外商業化里程碑付款及基於大中華區銷售淨額的分層提成。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account